The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.
 
Daniel R Stellato
Research Funding - Amgen (Inst); ARIAD (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Novartis (Inst); Sanofi (Inst); Sanofi Pasteur (Inst); Seagen (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Novartis
 
Lisa McGarry
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Hui Huang
Employment - ARIAD
Stock and Other Ownership Interests - ARIAD
 
Shaina Hastings
Research Funding - Amgen (Inst); ARIAD (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Novartis (Inst); Sanofi (Inst); Sanofi Pasteur (Inst); Seagen (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Novartis
 
Thomas E. Delea
Consulting or Advisory Role - Novartis (Inst)
Research Funding - Amgen (Inst); ARIAD (Inst); GlaxoSmithKline (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Novartis (Inst); Sanofi (Inst); Sanofi Pasteur (Inst); Seagen (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Novartis